Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 4/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568572 | 0.96 | KDM4E (0.41) | KDM4ELMNAHTTMTNR1AMTNR1B | |
| SCHEMBL3709676 | 0.93 | KDM4E (0.43) | KDM4ELMNAHTTMTNR1AMTNR1B | |
| SCHEMBL4568585 | 0.91 | PPARG (0.40) | ENPP2 | |
| SCHEMBL4568505 | 0.90 | MTNR1A (0.43) | KDM4ELMNAHTTMTNR1AMTNR1B | |
| SCHEMBL4568573 | 0.89 | ENPP2 (0.42) | KDM4ELMNAHTTMTNR1AMTNR1B | |
| SCHEMBL3713247 | 0.88 | MTNR1A (0.44) | KDM4ELMNAHTTMTNR1AMTNR1B | |
| SCHEMBL4568589 | 0.87 | PTGS1 (0.39) | MTNR1AMTNR1BENPP2DHODHGPR35 | |
| SCHEMBL4568494 | 0.87 | MTNR1A (0.43) | KDM4ELMNAMTNR1AMTNR1BCYP11B1 | |
| SCHEMBL4568556 | 0.87 | MTNR1A (0.43) | MTNR1AMTNR1BCYP11B1CYP11B2 | |
| SCHEMBL3714666 | 0.87 | PPARG (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | KDM4E 3521/4885LMNA 4472/4885HTT 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.